Mourits M J, De Vries E G, Willemse P H, Ten Hoor K A, Hollema H, Van der Zee A G
Department of Obstetrics and Gynecology, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Obstet Gynecol. 2001 May;97(5 Pt 2):855-66. doi: 10.1016/s0029-7844(00)01196-0.
To review the literature on tamoxifen side effects on the female genital tract and psychosexual function in premenopausal and postmenopausal women.
We used the English-language literature in MEDLINE and reference lists from selected articles. Search terms included: "tamoxifen and estrogen receptor," "transcription activation," "premenopause," "postmenopause," "vaginal epithelium," "uterus," "endometrial hyperplasia," "polyps," "endometrial cancer," "sonography," "sonohysterography," "hysteroscopy," "myometrium," "myoma," "sarcoma," "endometriosis," "ovarian cysts," "hot flushes," "concentration problems," "sleep disturbance," "vaginal dryness," "sexual function," "libido," "dyspareunia," and "quality of life." No study-type restrictions were imposed.
With respect to clinical studies we included case cohort studies, observational studies; if no trials were available on a subject, case reports published in peer-reviewed journals were selected. For the discussion on endometrial surveillance of tamoxifen users, letters and editorials published in peer-reviewed journals also were used. Subjects of interest were mechanism of action of tamoxifen, tamoxifen and the vaginal epithelium, endometrium, mesenchymal tumors of the uterus, ovaries, sexual function, and vasomotor instability.
TABULATION, INTEGRATION, AND RESULTS: Eligible studies were analyzed to determine their usefulness in this review. Data from trials that evaluated tamoxifen side effects on specific genital tissues were combined, with special interest in differentiation of side effects in premenopausal and postmenopausal women. Weighted estimates of severity and extent of side effects were usually not possible because of lack of randomized trials. Only the risk of endometrial cancer in relation to tamoxifen treatment could be estimated.
The gynecologic side effects of tamoxifen are diverse and reflect the complexity of its mechanism of action, with agonistic and antagonistic effects on various tissues, depending on the ambient estradiol concentration and hence menopausal status of the patient. The most frequently reported side effect was hot flushes, and the most worrisome gynecologic side effect was a two- to three-fold increased risk of endometrial cancer in postmenopausal women. Despite its side effects, the benefits of tamoxifen in controlling breast cancer or prevention of its relapse are still without debate.
综述关于他莫昔芬对绝经前和绝经后女性生殖系统及心理性功能副作用的文献。
我们使用了MEDLINE中的英文文献以及所选文章的参考文献列表。检索词包括:“他莫昔芬与雌激素受体”、“转录激活”、“绝经前”、“绝经后”、“阴道上皮”、“子宫”、“子宫内膜增生”、“息肉”、“子宫内膜癌”、“超声检查”、“宫腔超声造影”、“宫腔镜检查”、“子宫肌层”、“肌瘤”、“肉瘤”、“子宫内膜异位症”、“卵巢囊肿”、“潮热”、“注意力不集中问题”、“睡眠障碍”、“阴道干燥”、“性功能”、“性欲”、“性交困难”以及“生活质量”。未施加研究类型限制。
对于临床研究,我们纳入了病例队列研究、观察性研究;如果某一主题没有试验可用,则选择发表在同行评审期刊上的病例报告。对于关于他莫昔芬使用者子宫内膜监测的讨论,也使用了发表在同行评审期刊上的信函和社论。感兴趣的主题是他莫昔芬的作用机制、他莫昔芬与阴道上皮、子宫内膜、子宫间叶肿瘤、卵巢、性功能以及血管舒缩不稳定。
制表、整合与结果:对符合条件的研究进行分析以确定其在本综述中的有用性。合并了评估他莫昔芬对特定生殖组织副作用的试验数据,特别关注绝经前和绝经后女性副作用的差异。由于缺乏随机试验,通常无法对副作用的严重程度和范围进行加权估计。仅能估计与他莫昔芬治疗相关的子宫内膜癌风险。
他莫昔芬的妇科副作用多种多样,反映了其作用机制的复杂性,根据环境雌二醇浓度以及患者的绝经状态,对不同组织具有激动和拮抗作用。最常报告的副作用是潮热,最令人担忧的妇科副作用是绝经后女性子宫内膜癌风险增加两到三倍。尽管有副作用,但他莫昔芬在控制乳腺癌或预防其复发方面的益处仍无可争议。